Filing Details

Accession Number:
0001209191-20-058263
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-11-13 15:53:51
Reporting Period:
2020-11-12
Accepted Time:
2020-11-13 15:53:51
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1358762 Reata Pharmaceuticals Inc RETA Pharmaceutical Preparations (2834) 113651945
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1689402 Jr. D. William Mcclellan 5320 Legacy Drive
Plano TX 75024
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Class A Common Stock Acquisiton 2020-11-12 4,000 $0.00 4,000 No 4 C Direct
Class A Common Stock Disposition 2020-11-12 2,542 $172.44 1,458 No 4 S Direct
Class A Common Stock Disposition 2020-11-12 970 $173.21 488 No 4 S Direct
Class A Common Stock Disposition 2020-11-12 488 $174.82 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Class B Common Stock Stock Option (right to buy) Disposition 2020-11-12 4,000 $0.00 4,000 $25.52
Class A Common Stock Class B common stock Acquisiton 2020-11-12 4,000 $25.52 4,000 $0.00
Class A Common Stock Class B common stock Disposition 2020-11-12 4,000 $0.00 4,000 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
2,000 2027-06-14 No 4 M Direct
4,000 No 4 M Direct
0 No 4 C Direct
Footnotes
  1. The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $171.88 to $172.86. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $172.88 to $173.87. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $173.91 to $174.15. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  5. The options vested in 4 equal installments on September 14, 2017, December 14, 2017, March 14, 2018, and June 14, 2018.